2
Indication details
- Combined Agent(s)
- Erlotinib
- Control Arm
- Erlotinib
- FDA Therapeutic Indication
- In combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations
- Tumour Type
-
Thoracic Malignancies
- Tumour Sub-type
- Non-small-cell Lung Cancer
- Tumour Stage
- Unresectable advanced, recurrent or metastatic
- Tumour Sub-Group
- EGFR+
- Trial Name
- JO25567
- NCT Number
- JapicCTI-111390 (Japan Pharmaceutical Information Center)
- Trial Phase
- Phase II
Approval details
- FDA Approval
- Not FDA approved
- EMA Approval
- EMA (CHMP) April 2016 EC decision June 2016
Primary Outcome(s)
- Primary Outcome(s)
- PFS
- Evaluated Outcome
- PFS
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 9.8 months
- PFS Gain
- 6.6 months
- PFS HR
- 0.52 (0.35-0.76)
- OS Control
- 47.0 months
- OS Gain
- 0.4 months
- OS HR
- 0.81 (0.53-1.23) Not significant
Adjustments
- QoL Comment
-
No improvement in QoL
- Toxicity Comment
-
Deteriorated toxicity profile not reaching the toxicity thresholds for penalty
Score (after adjustments)
- Preliminary non-curative score
-
3
- Only improved PFS mature data shows no OS advantage and no improved QoL
- 1-
- Non-curative score
-
2
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 69
- Scorecard version
- 1
- Issue date
- 11.12.2018
- Last update
- 17.08.2023
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.